Basel, Switzerland 4/4/07; Gaithersburg, MD 4/4/07—Roche has signed a definitive agreement to acquire BioVeris for $21.50 per share in cash, or approximately $600 million. BioVeris offers reagents and instruments for diagnostic testing and research based on its electrochemiluminescence technology (ECL). Roche Diagnostics stated that the acquisition will allow it to expand its immunochemistry business from […]